Sanaria Inc.
- Company typePrivate
- Founded2003
- HeadquartersRockville, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Sanaria Inc. firmographics
Firmographics- Name
- Sanaria Inc.
- Legal name
- Sanaria Inc.
- Website
- https://sanaria.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Sanaria Inc. industry classification
Industry- Product category
- Malaria Vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Travel & Tropical Disease Vaccines (HLAIAEAE)
- akta.pro secondary industries
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ)
Keywords
Where Sanaria Inc. is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Sanaria Inc. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure
Revenue model
- Research Reagents and Products: Sale of aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites, Plasmodium reagents, Anopheles mosquitoes, assay services, and custom manufacturing to research institutions
- Vaccine Development: Development of malaria vaccines for prevention in individuals and in combination with other malaria control measures to halt transmission and eliminate malaria from communities
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Research reagents and services for the scientific community |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Sanaria Inc. product offering
Product offeringCore offering
Sanaria develops whole-parasite malaria vaccines based on its proprietary Plasmodium falciparum sporozoite (PfSPZ) platform, including radiation-attenuated (PfSPZ Vaccine), chemo-attenuated (PfSPZ-CVac), and genetically engineered late-arresting (PfSPZ-LARC2) candidates. The company also manufactures and sells a family of aseptic, purified, cryopreserved malaria research reagents, assay services (aIFA, aISI, ELISA), PfSPZ Challenge mosquitoes, antibodies, and custom manufacturing services to research institutions worldwide.
Product overview
Sanaria Inc. is a biotechnology company developing whole-parasite malaria vaccines and providing related research products and services. The core product portfolio includes three vaccine candidates in various clinical stages: Sanaria® PfSPZ Vaccine (radiation-attenuated, Phase 2), Sanaria® PfSPZ-LARC2 Vaccine (genetically engineered, single-dose, Phase 1), and Sanaria® PfSPZ-CVac (chemo-attenuated with antimalarial drugs, Phase 2). Supporting the vaccine development pipeline, Sanaria offers a comprehensive family of research reagents and services including PfSPZ Reagents, Plasmodium Reagent Slides, PfSPZ Challenge Mosquitoes, Anopheles Reagents, Antibodies (MAbPfEXP-1, MAbPfCelTOS), and assay services (aIFA, aISI, ELISA). All products are manufactured in a cGMP-compliant industrial setting.
Differentiator
Problem solved
Functional benefit
Brands
- Sanaria Family of Products and Services: A catalog of reagents and services including PfSPZ Reagents, Plasmodium Reagent Slides, Assay Services (aIFA, aISI, ELISA), PfSPZ Challenge Mosquitoes, Anopheles Reagents, Antibodies, and Custom Services for malaria research.
Products and services
- Sanaria PfSPZ Vaccine Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoite vaccine designed to prevent malaria infection; currently in Phase 2 clinical studies.
- Sanaria PfSPZ-LARC2 Vaccine Late arresting replication competent whole-parasite malaria vaccine designed to provide high-level protection against Plasmodium falciparum with a single dose. Developed in collaboration with Seattle Children's Research Institute.
- Sanaria PfSPZ-CVac Infectious PfSPZ vaccine administered with malaria chemoprophylaxis (chloroquine or pyrimethamine); currently in Phase 2 clinical studies and demonstrated 100% protective efficacy against heterologous controlled human malaria infection 12 weeks after vaccination.
- Sanaria PfSPZ Reagents Aseptic, purified, vialed, cryopreserved, attenuated and non-attenuated Plasmodium falciparum sporozoites for laboratory-based research studies. Sold to research institutions worldwide.
- Sanaria Plasmodium Reagent Slides
Quantifiable outcome
- 77% protection rate against heterologous controlled human malaria infection 12 weeks after vaccination with PfSPZ-CVac
- +3 more outcomes
Companies that use Sanaria Inc.
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Sanaria Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Sanaria Inc. partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- PATH Malaria Vaccine Initiative (MVI)corePartnership established in 2006 to accelerate development of Sanaria's unique malaria vaccine candidate. MVI and Sanaria conducted initial safety and test-of-concept trials. Partnership included opening of clinical manufacturing facility in 2007.
- Seattle Children's Research InstitutecoreCo-development of PfSPZ-LARC2 Vaccine - a whole malaria parasite vaccine strain that infects the liver and gets completely stuck, unable to cause blood infection. Joint publication in EMBO Molecular Medicine March 2024. Co-host i-PfSPZ-C meetings.
- Government of Equatorial GuineacoreLong-term partnership since 2004 for the Bioko Island Malaria Elimination Project (BIMEP). Partnership includes Marathon Oil, Noble Energy, AMPCO, and Equatorial Guinea LNG. Dedicated to elimination of malaria from Bioko Island where it was a leading cause of morbidity and mortality.
- University of Tübingen / German Center for Infection Research (DZIF)coreKey collaborator on PfSPZ-CVac vaccine development and clinical trials. Professor Peter Kremsner leads studies demonstrating 77-100% protective efficacy. DZIF workshop on malaria vaccine development focuses on PfSPZ-LARC2 Vaccine at Paul-Ehrlich-Institut.
- International PfSPZ Consortium (i-PfSPZ-C)coreGlobal collaboration network with semi-annual meetings. 2025 meeting in Toronto brought together 48 scientists from 11 countries. Consortium includes researchers from US, Europe, and Africa coordinating vaccine and clinical development strategies.
- Malaria No MoreminorAdvocacy organization dedicated to ending malaria. Organized World Malaria Day Exhibition at Rayburn House Office Building in Washington DC. CEO Bill Steiger visited Sanaria facilities in May 2026.
- Protein Potential, LLCcoreCo-located in Rockville, Maryland with Sanaria. Collaboration on COVID-19 vaccine development (OraCOV vaccine). Dr. Kim Lee Sim serves as President/CSO at Protein Potential and Executive VP of Process Development and Manufacturing at Sanaria.
- Malaria Research and Training Center (MRTC), MalicoreCollaborator on NIH-funded PfSPZ-CVac malaria vaccine development. Clinical trials in Mali including studies in adults and women of childbearing potential.
- Groupe de Recherche Action en Santé (GRAS), Burkina FasominorPhysician-scientists at GRAS in Burkina Faso conducting initial safety evaluations of PfSPZ-LARC2 Vaccine in 30 adult Burkinabé participants.
- U.S. Naval Medical Research CentercoreClinical trial site partner. Phase 1 trial conducted at US Naval Medical Research Center Clinical Trials Center in Bethesda.
- University of Maryland School of MedicinecoreCollaborator on clinical trials and NIH-funded research. Phase 1 trial site at Center for Vaccine Development in Baltimore.
Scale indicators11 records
Recent moves3 records
Expansion highlights5 records
Sanaria Inc. competitors and assessment
Company assessmentDirect peers
- GSK: GSK developed RTS,S/AS01 (Mosquirix), the first WHO-recommended malaria vaccine targeting P. falciparum in children. It is the most directly comparable competitor to Sanaria's PfSPZ platform in the same indication and end market.
- Serum Institute of India: Co-developer and manufacturer of the R21/Matrix-M malaria vaccine with Oxford's Jenner Institute, approved in multiple African countries at sub-$5 per dose. Directly competes with Sanaria in the same P. falciparum pediatric market with a scaled, low-cost alternative.
- University of Oxford (Jenner Institute): Originator of the R21/Matrix-M malaria vaccine, which has achieved WHO prequalification and is being deployed across endemic regions. Direct peer given overlapping P. falciparum vaccine target and global-health funding ecosystem.
Emerging players
- BioNTech: Developing mRNA-based malaria vaccine candidates (BNT165) toward clinical evaluation. Comparable as a next-generation platform challenger in the malaria vaccine race, though with a different technology architecture than Sanaria's whole-parasite approach.
- Moderna: Advancing mRNA-1640 and related malaria mRNA vaccine candidates. Operates in the same global-health infectious-disease space with a different technology platform, pursuing the same P. falciparum indication.
Broad incumbents
- Novavax: Vaccine platform company with Matrix-M adjuvant technology underpinning R21/Matrix-M and broader infectious-disease pipeline. Comparable as an established vaccine platform player in global health, though more diversified across indications than Sanaria.
Regional players
- Bharat Biotech: Indian vaccine manufacturer with a malaria vaccine candidate (BBV87) and a broad global-health portfolio. Comparable as a manufacturer of cost-effective vaccines for endemic-region markets, with regional strengths overlapping Sanaria's Africa/Asia clinical footprint.
Others
- PATH Malaria Vaccine Initiative: Global-health non-profit product development partner and long-standing Sanaria collaborator (PATH MVI partnership since 2006). Comparable as an influential funder/partner shaping malaria vaccine development strategy and donor priorities.
- Leidos Holdings (via contracted NIAID work): Operates vaccine biodefense and infectious-disease R&D programs including malaria-related work for U.S. government clients. Comparable as a contractor/ecosystem participant in malaria and emerging infectious disease research adjacent to Sanaria's NIAID-funded pipeline.
- Protein Potential, LLC: Co-located Rockville biotech and Sanaria co-developer of the OraCOV oral COVID-19 vaccine, with shared executive leadership (Dr. B. Kim Lee Sim). Comparable as a closely adjacent vaccine development partner using similar platforms.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Sanaria Inc. social profiles
Digital presenceSanaria Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sanaria Inc. leadership team
Management profileNumber of profiles
Profiles4 records
Sanaria Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sanaria Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sanaria Inc.
What does Sanaria Inc. do?
Sanaria develops whole-parasite malaria vaccines based on its proprietary Plasmodium falciparum sporozoite (PfSPZ) platform, including radiation-attenuated (PfSPZ Vaccine), chemo-attenuated (PfSPZ-CVac), and genetically engineered late-arresting (PfSPZ-LARC2) candidates. The company also manufactures and sells a family of aseptic, purified, cryopreserved malaria research reagents, assay services (aIFA, aISI, ELISA), PfSPZ Challenge mosquitoes, antibodies, and custom manufacturing services to research institutions worldwide.
Is Sanaria Inc. a public or private company?
Sanaria Inc. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Sanaria Inc. founded?
Sanaria Inc. was founded in 2003. It employs 51 to 100 people.
Where is Sanaria Inc. based?
Sanaria Inc. is headquartered in Rockville, United States, in the North America region.
How does Sanaria Inc. make money?
Two revenue lines are on record. Research Reagents and Products are the primary driver. The others are vaccine Development.
Who are Sanaria Inc.'s main competitors?
Direct peers on record are GSK, Serum Institute of India and University of Oxford (Jenner Institute). Emerging players are BioNTech and Moderna. Novavax is listed as a broad incumbent. Bharat Biotech is listed as a regional player. Others are PATH Malaria Vaccine Initiative, Leidos Holdings (via contracted NIAID work) and Protein Potential, LLC.
Does Sanaria Inc. have an API?
No public API is recorded for Sanaria Inc..
What industry is Sanaria Inc. in?
Sanaria Inc.'s product category is Malaria Vaccines. Its primary akta.pro industry code is HLAIAEAE, Travel & Tropical Disease Vaccines, with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.